NasdaqCM · Biotechnology

Cingulate Inc (CING)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+285.6%

$21.40 average target

$5.55+0.22 (+4.1%)Latest market snapshot · Yahoo Finance

Market cap$80.7M

Cash$28.4M

Quarterly burn$6.9M

Pipeline assets3

Short float16.8%

Latest coverage

News & Press Releases

External sources

Aug 19, 2026

CING: Second Quarter ResultsZacks Small Cap Research

Aug 13, 2026

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessGlobeNewswire

Aug 11, 2026

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic ProfileGlobeNewswire

Continue with BioPharma ProUnlock 5 more recent stories and press releases.

Unlock Pro

Company profile

About Cingulate Inc

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.